Table II.
Adjustment factors |
Loge resistin | Loge adiponectin | ||
---|---|---|---|---|
HR* | P | HR* | P | |
No adjustment | 1.33 (1.17–1.52) | <.001 | 0.95 (0.83–1.09) | .439 |
Age and sex | 1.19 (1.04–1.37) | .011 | 0.91 (0.78–1.06) | .205 |
Age, sex, BMI | 1.15 (1.00–1.32) | .050 | 0.97 (0.83–1.14) | .719 |
AF risk score | 1.17 (1.02–1.34) | .028 | 0.95 (0.81–1.10) | .478 |
AF risk score and CRP | 1.14 (0.99–1.31) | .073 | 0.95 (0.82–1.11) | .547 |
AF risk score and interim heart failure | 1.16 (1.01–1.33) | .034 | 0.95 (0.81–1.11) | .486 |
AF, Atrial fibrillation; BMI, body mass index.
AF risk score (age, sex, body mass index, systolic blood pressure, treatment of hypertension, PR interval, clinically significant cardiac murmur, and heart failure).26
Hazard ratios are relative to 1 SD (0.41 ng/mL for resistin and 0.62 µg/mL for adiponectin) increase in loge resistin or adiponectin, respectively, and 95% CI.